Susan Lana
Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dog Diseases | 42 | 2025 | 140 | 6.520 |
Why?
| | Osteosarcoma | 15 | 2022 | 100 | 2.600 |
Why?
| | Dogs | 45 | 2025 | 517 | 1.790 |
Why?
| | Lymphoma | 11 | 2021 | 251 | 1.510 |
Why?
| | Bone Neoplasms | 10 | 2022 | 272 | 1.420 |
Why?
| | Cyclophosphamide | 6 | 2019 | 275 | 1.000 |
Why?
| | Lymphoma, B-Cell | 4 | 2019 | 150 | 0.850 |
Why?
| | Doxorubicin | 8 | 2019 | 416 | 0.810 |
Why?
| | Hemangiosarcoma | 3 | 2013 | 27 | 0.710 |
Why?
| | Cats | 6 | 2017 | 226 | 0.640 |
Why?
| | Antineoplastic Agents, Alkylating | 2 | 2017 | 76 | 0.560 |
Why?
| | Cat Diseases | 5 | 2006 | 37 | 0.490 |
Why?
| | Animals | 52 | 2025 | 38107 | 0.460 |
Why?
| | Carboplatin | 2 | 2021 | 168 | 0.430 |
Why?
| | Maxillary Neoplasms | 1 | 2014 | 9 | 0.430 |
Why?
| | Skull Neoplasms | 1 | 2014 | 20 | 0.430 |
Why?
| | Mandibular Neoplasms | 1 | 2014 | 23 | 0.420 |
Why?
| | Abetalipoproteinemia | 1 | 2013 | 4 | 0.410 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1998 | 0.370 |
Why?
| | Mast-Cell Sarcoma | 3 | 2010 | 9 | 0.360 |
Why?
| | Extremities | 3 | 2022 | 142 | 0.340 |
Why?
| | Carcinoma | 4 | 2006 | 225 | 0.330 |
Why?
| | Cisplatin | 2 | 2004 | 347 | 0.300 |
Why?
| | Skin Neoplasms | 4 | 2006 | 806 | 0.270 |
Why?
| | Sarcoma | 4 | 2023 | 209 | 0.270 |
Why?
| | Antineoplastic Agents | 7 | 2015 | 2219 | 0.260 |
Why?
| | Splenic Neoplasms | 1 | 2007 | 6 | 0.260 |
Why?
| | Etoposide | 1 | 2007 | 169 | 0.250 |
Why?
| | Disease-Free Survival | 4 | 2019 | 778 | 0.240 |
Why?
| | Administration, Oral | 4 | 2017 | 872 | 0.240 |
Why?
| | Head and Neck Neoplasms | 1 | 2012 | 563 | 0.240 |
Why?
| | Thymoma | 1 | 2006 | 38 | 0.240 |
Why?
| | Matrix Metalloproteinase 2 | 3 | 2002 | 57 | 0.240 |
Why?
| | Receptors, Antigen | 1 | 2006 | 15 | 0.240 |
Why?
| | Lymphoma, T-Cell | 2 | 2021 | 31 | 0.240 |
Why?
| | Mediastinal Neoplasms | 1 | 2006 | 54 | 0.230 |
Why?
| | Soft Tissue Neoplasms | 2 | 2023 | 133 | 0.230 |
Why?
| | Matrix Metalloproteinase 9 | 3 | 2002 | 128 | 0.230 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2025 | 43 | 0.230 |
Why?
| | Complementary Therapies | 1 | 2006 | 93 | 0.220 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2025 | 38 | 0.220 |
Why?
| | Half-Life | 3 | 2017 | 157 | 0.220 |
Why?
| | Gene Rearrangement | 1 | 2006 | 156 | 0.220 |
Why?
| | Nose Neoplasms | 1 | 2004 | 22 | 0.210 |
Why?
| | Female | 35 | 2025 | 79499 | 0.210 |
Why?
| | Vincristine | 4 | 2019 | 148 | 0.200 |
Why?
| | Male | 34 | 2025 | 73396 | 0.200 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2025 | 1432 | 0.200 |
Why?
| | Pets | 2 | 2021 | 28 | 0.200 |
Why?
| | Area Under Curve | 2 | 2017 | 335 | 0.200 |
Why?
| | Neoplasms | 4 | 2007 | 2954 | 0.200 |
Why?
| | Prednisone | 4 | 2019 | 229 | 0.200 |
Why?
| | Histiocytoma, Malignant Fibrous | 1 | 2023 | 6 | 0.200 |
Why?
| | Treatment Outcome | 9 | 2022 | 11821 | 0.190 |
Why?
| | Brain Death | 1 | 2023 | 59 | 0.190 |
Why?
| | Flow Cytometry | 4 | 2019 | 1163 | 0.190 |
Why?
| | Combined Modality Therapy | 6 | 2021 | 1271 | 0.180 |
Why?
| | Pathology, Veterinary | 1 | 2021 | 2 | 0.180 |
Why?
| | Immunophenotyping | 4 | 2021 | 324 | 0.170 |
Why?
| | Veterinarians | 1 | 2021 | 12 | 0.170 |
Why?
| | Thyroid Neoplasms | 1 | 2025 | 380 | 0.170 |
Why?
| | Wilms Tumor | 1 | 2022 | 91 | 0.170 |
Why?
| | Analgesia | 1 | 2022 | 106 | 0.160 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2023 | 530 | 0.160 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2021 | 70 | 0.160 |
Why?
| | Immunity, Humoral | 1 | 2021 | 121 | 0.160 |
Why?
| | Neoplasm Staging | 5 | 2010 | 1488 | 0.160 |
Why?
| | Tissue and Organ Procurement | 1 | 2023 | 305 | 0.150 |
Why?
| | Anemia | 2 | 2013 | 190 | 0.150 |
Why?
| | Tobacco Smoking | 1 | 2019 | 29 | 0.150 |
Why?
| | Mutation, Missense | 1 | 2021 | 334 | 0.150 |
Why?
| | Retrospective Studies | 13 | 2022 | 17438 | 0.150 |
Why?
| | Goals | 1 | 2021 | 187 | 0.150 |
Why?
| | Italy | 4 | 2023 | 118 | 0.150 |
Why?
| | Sirolimus | 1 | 2021 | 282 | 0.150 |
Why?
| | Veterinary Medicine | 1 | 2019 | 12 | 0.140 |
Why?
| | Smokers | 1 | 2019 | 139 | 0.140 |
Why?
| | Vaping | 1 | 2019 | 81 | 0.140 |
Why?
| | Survival Analysis | 6 | 2011 | 1378 | 0.140 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2021 | 259 | 0.130 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2019 | 112 | 0.130 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 1997 | 21 | 0.130 |
Why?
| | Kidney Neoplasms | 1 | 2022 | 419 | 0.130 |
Why?
| | Injections, Intraperitoneal | 1 | 2017 | 115 | 0.130 |
Why?
| | Lymph Nodes | 3 | 2016 | 511 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2004 | 628 | 0.130 |
Why?
| | Pain | 2 | 2022 | 790 | 0.130 |
Why?
| | Biomarkers | 3 | 2008 | 4340 | 0.130 |
Why?
| | Biological Availability | 1 | 2017 | 146 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 2 | 2022 | 3926 | 0.120 |
Why?
| | Administration, Intravenous | 1 | 2017 | 172 | 0.120 |
Why?
| | Prognosis | 6 | 2011 | 4351 | 0.120 |
Why?
| | Prospective Studies | 3 | 2021 | 8123 | 0.110 |
Why?
| | Hospice Care | 1 | 2019 | 230 | 0.110 |
Why?
| | Immunity, Innate | 1 | 2021 | 844 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2016 | 237 | 0.110 |
Why?
| | Drug Administration Schedule | 3 | 2014 | 790 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2016 | 157 | 0.110 |
Why?
| | Alkaline Phosphatase | 1 | 2015 | 144 | 0.100 |
Why?
| | Acanthocytes | 1 | 2013 | 1 | 0.100 |
Why?
| | Tandem Mass Spectrometry | 1 | 2017 | 576 | 0.100 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2016 | 195 | 0.100 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2015 | 266 | 0.100 |
Why?
| | Radiotherapy | 1 | 2014 | 209 | 0.100 |
Why?
| | Survival Rate | 5 | 2021 | 2092 | 0.100 |
Why?
| | Polymerase Chain Reaction | 2 | 2006 | 1031 | 0.100 |
Why?
| | Fas Ligand Protein | 1 | 2012 | 61 | 0.090 |
Why?
| | Digestion | 1 | 2012 | 17 | 0.090 |
Why?
| | Fabaceae | 1 | 2012 | 12 | 0.090 |
Why?
| | Animal Feed | 1 | 2012 | 50 | 0.090 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 426 | 0.090 |
Why?
| | Infusions, Intravenous | 2 | 2011 | 432 | 0.090 |
Why?
| | Genes, MHC Class II | 1 | 2011 | 77 | 0.080 |
Why?
| | Delayed-Action Preparations | 2 | 2004 | 192 | 0.080 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2011 | 175 | 0.080 |
Why?
| | Stromal Cells | 2 | 2002 | 123 | 0.080 |
Why?
| | Random Allocation | 1 | 2011 | 366 | 0.080 |
Why?
| | Genetic Therapy | 1 | 2012 | 303 | 0.080 |
Why?
| | Radiography | 1 | 2012 | 861 | 0.070 |
Why?
| | Surveys and Questionnaires | 3 | 2019 | 6073 | 0.070 |
Why?
| | Multivariate Analysis | 2 | 2006 | 1543 | 0.070 |
Why?
| | Foodborne Diseases | 1 | 2009 | 60 | 0.070 |
Why?
| | Chromosome Aberrations | 1 | 2009 | 167 | 0.070 |
Why?
| | Lymphocytosis | 1 | 2008 | 12 | 0.070 |
Why?
| | Glucose Transporter Type 1 | 1 | 2008 | 49 | 0.070 |
Why?
| | Lymphoproliferative Disorders | 1 | 2008 | 59 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1503 | 0.060 |
Why?
| | Microtubule-Associated Proteins | 1 | 2008 | 187 | 0.060 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2007 | 74 | 0.060 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2007 | 143 | 0.060 |
Why?
| | Histocytochemistry | 1 | 2006 | 77 | 0.060 |
Why?
| | Prevalence | 2 | 2019 | 2861 | 0.060 |
Why?
| | Lomustine | 1 | 2006 | 18 | 0.060 |
Why?
| | DNA, Neoplasm | 1 | 2006 | 160 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2009 | 1998 | 0.060 |
Why?
| | Lymphocyte Count | 1 | 2006 | 167 | 0.060 |
Why?
| | Mycosis Fungoides | 1 | 2006 | 63 | 0.060 |
Why?
| | Time Factors | 5 | 2010 | 7109 | 0.060 |
Why?
| | Neoplasm Proteins | 1 | 2008 | 444 | 0.050 |
Why?
| | Biomarkers, Tumor | 3 | 2021 | 1339 | 0.050 |
Why?
| | Risk Factors | 2 | 2021 | 10921 | 0.050 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 76 | 0.050 |
Why?
| | Incidence | 2 | 2005 | 2936 | 0.050 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2006 | 145 | 0.050 |
Why?
| | Diet | 1 | 2012 | 1273 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2004 | 222 | 0.050 |
Why?
| | Isoenzymes | 1 | 2004 | 294 | 0.050 |
Why?
| | Anal Gland Neoplasms | 1 | 2003 | 1 | 0.050 |
Why?
| | Lymphatic Metastasis | 1 | 2005 | 335 | 0.050 |
Why?
| | Colorado | 3 | 2019 | 4595 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2007 | 3647 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2023 | 38 | 0.050 |
Why?
| | Mutation | 2 | 2025 | 4093 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2021 | 931 | 0.050 |
Why?
| | Hospitals, Animal | 1 | 2022 | 2 | 0.050 |
Why?
| | Hospitals, Teaching | 1 | 2022 | 121 | 0.040 |
Why?
| | Chromium | 1 | 2001 | 18 | 0.040 |
Why?
| | Attitude | 1 | 2023 | 253 | 0.040 |
Why?
| | Thoracic Vertebrae | 1 | 2022 | 90 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2006 | 587 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2022 | 122 | 0.040 |
Why?
| | Information Systems | 1 | 2021 | 58 | 0.040 |
Why?
| | Muscle Development | 1 | 2021 | 114 | 0.040 |
Why?
| | Orosomucoid | 1 | 2000 | 10 | 0.040 |
Why?
| | Attitude to Health | 1 | 2023 | 421 | 0.040 |
Why?
| | Tissue Donors | 1 | 2023 | 425 | 0.040 |
Why?
| | Genomics | 1 | 2025 | 853 | 0.040 |
Why?
| | Carcinoma, Small Cell | 1 | 2000 | 172 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2021 | 429 | 0.040 |
Why?
| | Necrosis | 2 | 2012 | 243 | 0.040 |
Why?
| | Education, Veterinary | 1 | 2019 | 7 | 0.040 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2021 | 231 | 0.040 |
Why?
| | Iron | 1 | 2001 | 359 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2007 | 3416 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 344 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2006 | 1160 | 0.040 |
Why?
| | B-Lymphocytes | 3 | 2011 | 887 | 0.040 |
Why?
| | Humans | 8 | 2025 | 146342 | 0.030 |
Why?
| | Zinc | 1 | 2001 | 310 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2021 | 455 | 0.030 |
Why?
| | Ear, External | 1 | 1997 | 22 | 0.030 |
Why?
| | Cryotherapy | 1 | 1997 | 22 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2004 | 927 | 0.030 |
Why?
| | Dermatologic Surgical Procedures | 1 | 1997 | 25 | 0.030 |
Why?
| | Nose | 1 | 1997 | 67 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2021 | 747 | 0.030 |
Why?
| | Texas | 1 | 1997 | 280 | 0.030 |
Why?
| | Universities | 1 | 2019 | 451 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2019 | 442 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1730 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 1068 | 0.030 |
Why?
| | Biopsy | 1 | 1997 | 1075 | 0.030 |
Why?
| | Skin | 1 | 1997 | 701 | 0.020 |
Why?
| | Immunohistochemistry | 2 | 2008 | 1712 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2010 | 2113 | 0.020 |
Why?
| | Animal Nutritional Physiological Phenomena | 1 | 2012 | 13 | 0.020 |
Why?
| | Curriculum | 1 | 2019 | 1079 | 0.020 |
Why?
| | Cooking | 1 | 2012 | 62 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2011 | 89 | 0.020 |
Why?
| | Cell Size | 1 | 2011 | 95 | 0.020 |
Why?
| | Brain | 1 | 2023 | 2991 | 0.020 |
Why?
| | Thiazoles | 1 | 2010 | 139 | 0.020 |
Why?
| | Benzamides | 1 | 2010 | 226 | 0.020 |
Why?
| | Cytogenetics | 1 | 2009 | 12 | 0.020 |
Why?
| | Chromosomes, Mammalian | 1 | 2009 | 28 | 0.020 |
Why?
| | Piperidines | 1 | 2010 | 225 | 0.020 |
Why?
| | Feces | 1 | 2012 | 496 | 0.020 |
Why?
| | Trisomy | 1 | 2009 | 79 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5899 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2009 | 334 | 0.020 |
Why?
| | Body Weight | 1 | 2012 | 968 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2009 | 882 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 5246 | 0.020 |
Why?
| | Retinoblastoma Protein | 1 | 2007 | 63 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2012 | 2070 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 3545 | 0.020 |
Why?
| | Survivors | 1 | 2010 | 526 | 0.020 |
Why?
| | Gene Silencing | 1 | 2007 | 200 | 0.010 |
Why?
| | Patient Selection | 1 | 2010 | 728 | 0.010 |
Why?
| | Pyridines | 1 | 2010 | 610 | 0.010 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2008 | 299 | 0.010 |
Why?
| | Recurrence | 1 | 2008 | 1133 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 970 | 0.010 |
Why?
| | Cyclooxygenase 2 | 1 | 2004 | 166 | 0.010 |
Why?
| | Anal Sacs | 1 | 2003 | 1 | 0.010 |
Why?
| | United States | 1 | 2021 | 16136 | 0.010 |
Why?
| | Apocrine Glands | 1 | 2003 | 5 | 0.010 |
Why?
| | Apoptosis | 1 | 2012 | 2439 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2006 | 588 | 0.010 |
Why?
| | Sex Distribution | 1 | 2003 | 382 | 0.010 |
Why?
| | Blotting, Western | 1 | 2004 | 1177 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 2000 | 26 | 0.010 |
Why?
| | Immunodiffusion | 1 | 2000 | 13 | 0.010 |
Why?
| | Aged | 1 | 2021 | 26432 | 0.010 |
Why?
| | Hyperinsulinism | 1 | 2001 | 115 | 0.010 |
Why?
| | Glucose Tolerance Test | 1 | 2001 | 360 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 22557 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2006 | 1150 | 0.010 |
Why?
| | Palliative Care | 1 | 2007 | 1032 | 0.010 |
Why?
| | Killer Cells, Natural | 1 | 2001 | 481 | 0.010 |
Why?
| | Regression Analysis | 1 | 2000 | 999 | 0.010 |
Why?
| | Adult | 1 | 2021 | 41087 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2000 | 778 | 0.010 |
Why?
| | Quality of Life | 1 | 2007 | 3200 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2003 | 2675 | 0.000 |
Why?
|
|
Lana's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|